| Sensitivity | Specificity | PPV | NPV | Accuracy |
---|---|---|---|---|---|
Biomarker screening group (n = 88) | |||||
 %, (n/N) | 96.4 (27/28) | 98.3 (59/60) | 96.4 (27/28) | 98.3 (59/60) | 97.7 (86/88) |
 95% CI | 80.8–100.0 | 90.3–100.0 | 80.8–100.0 | 90.3–100.0 | 91.6–99.9 |
Biomarker validation group (n = 216) | |||||
 %, (n/N) | 88.2 (67/76) | 92.1 (129/140) | 85.9 (67/78) | 93.5 (129/138) | 90.7 (196/216) |
 95% CI | 78.8–93.9 | 86.3–96.7 | 76.3–92.1 | 87.9–96.7 | 86.1–94.0 |
Clinical validation group (n = 194) | |||||
 %, (n/N) | 85.7 (78/91) | 91.3 (94/103) | 89.7 (78/87) | 87.9 (94/107) | 88.7 (172/194) |
 95% CI | 76.9–91.6 | 84.0–95.5 | 81.3–94.7 | 80.2–92.9 | 83.4–92.5 |